key: cord-0732711-jheg3ntd authors: Shah, Naveed Nazir; Dar, Khurshid Ahmad; Quibtiya, Syed; Azad, Aaliya Mohi Ud Din; Mushtaq, Mehvish; Bashir, Showkeen Muzamil; Rather, Muzafar Ahmad; Ali, Sofi Imtiyaz; Sheikh, Wajid Mohammad; Nabi, Showkat Ul title: Repurposing of Mycobacterium indicus pranii for the severe form of COVID‐19 patients in India: A cohort study date: 2022-01-07 journal: J Med Virol DOI: 10.1002/jmv.27547 sha: eb8ba7b28e30ea481b6b8ab56993abf3bc682c26 doc_id: 732711 cord_uid: jheg3ntd Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces the production of proinflammatory cytokines, which results in a cytokine storm, and immune‐modulators like Mycobacterium indicus pranii (MIP) might ameliorate coronavirus disease of 2019 (COVID‐19) related cytokine storm. Therefore, the present study evaluates whether MIP offers an advantage in the treatment of severe COVID‐19 patients infected with SARS‐CoV‐2. A prospective MIP cohort study was conducted in chest disease hospitals in Srinagar, Jammu and Kashmir, India. In the present prospective, randomized clinical study, critically severe COVID‐19 patients were divided into two groups, the MIP group (n = 105) and the best standard treatment (BST) group (n = 210). Procalcitonin, ferritin, high‐sensitive C‐reactive protein, D‐dimer levels, and interleukin levels on 5th‐day posttreatment were significantly reduced in the MIP group compared to the BST group. Compared to the BST group, 105 consecutive patients with severe COVID‐19 in the MIP group reported early weaning off ventilation, resolution of chest architecture (computed tomography [CT] scan), a significant increase in SpO(2) levels, and decreased mortality with a hazard ratio: 0.234 (95% confidence interval: 0.264–2.31) (p = 0.001). MIP restored SpO(2), immune/inflammatory response, normalized lung abnormalities (chest CT scan), and reduced mortality without any serious complications. However, there is a need for placebo‐controlled double‐blind and controlled clinical trials to confirm the efficacy. The global pandemic of coronavirus disease of 2019 (COVID- 19) originated from Wuhan, China, in December 2019, which engulfed the whole continent within a span of 4 months. 1 At the time of preparation of this draft (June 12, 2021), the total number of 176 112 919 cases are recorded so far with 3 802 235 deaths, furthermore, at present most severely affected countries include USA, India, and Brazil. 2-4 Throughout the world, more than 300 clinical trials have been conducted in different parts of the world using a wide range of antiviral drugs and other classes of drugs against COVID-19, but till now, an effective therapy against COVID-19 has not been developed. Currently, COVID-19 is managed by a diverse set of therapeutic regimens, which includes plasma therapy, traditional medicines, and various repurposed pharmacological drugs. 5 In spite of these attempts, Food and Drug Administration (FDA) has officially approved only nucleoside analog remdesivir, but its effectiveness is still a debate. 6 patients. Although some vaccine trials have reported very promising results in preclinical stages and have postulated that these candidate vaccines can provide effective protection against severe forms of COVID-19. 8 As there is every chance that the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus can mutate and change antigenically hence search for the vaccine will be a never lasting attempt. SARS COV-2 have a similar pathogenetic pathway like that of Middle East respiratory syndrome coronavirus and SARS-CoV-1, which involves hyper-activation of inflammatory pathways, which results in cytokine storm and consequently multiple organ failure. 9,10 SARS-CoV-2 is believed to bind with toll-like receptors and causes activation of the inflammasome and henceforth production of proinflammatory cytokines. 11 Plethora of studies have proposed immune deregulation as an independent risk factor for negative outcomes in COVID-19, henceforth various immune modulators have been proposed to have a beneficial role in COVID-19 or might be helpful in inhibiting the severe progression of diseases caused by SARS-CoV-2. 3 But the majority of these immune mod- ulators are yet to be evaluated in actual clinical conditions. In India, owing to the dramatic increase in the number of cases and unavailability of specific therapy against COVID-19, the Indian government proposed Mycobacterium indicus pranii (MIP; commercially available as Sepsivac), which is prepared from heat-killed MIP (formerly known as Mycobacterium W), will be tested on 50 COVID-19 patients at two centers in India. 9 MIP is an easily cultivatable and nonpathogenic microorganism grouped with other beneficial Mycobacterium (M. fortuitum, M. smegmatis, and M. vaccae) in Runyon Group IV. Furthermore, MIP was extensively evaluated for its biochemical and immunological properties and has been successfully used as an immune modulator in a wide spectrum of diseases. 12 MIP was earlier developed for the treatment of sepsis caused by gram-negative bacteria and has been already approved for a phase-III clinical trial in India. 13 MIP was used as a vaccine for leprosy warts caused by human papillomavirus 14, 15 and as a prophylactic drug against pulmonary tuberculosis. 16 The rationale of using MIP is based on the analogy that in both gramnegative sepsis and severe progression of COVID-19, immunedysregulation mediated by cytokine storm plays an important role in disease progression and mortality. Recently a study has found that candidate drug offers protection against COVID-19 via upregulation of adaptive natural killer cells and regulates the generation of robust cytokines, which include interleukin-2 (IL-2) and interferon-γ (IFN-γ). 13, 16 To further support this, in situ studies have found differential expression of cytokine genes in the presence of MIP, and these studies have attributed differential expression of cytokines to modulation of immune response evoked by MIP. 17 Immunomodulatory action of MIP has been shown to be mediated by upregulation of Th1 immune response and simultaneously downregulation of Th2 immune response which results in upregulation of inhibitor Κappa Kinase-α andβ in patients infected with pulmonary form of tuberculosis. 18 Elsewhere, in Human Immunodeficiency Virus patients, MIP in combination with antiretroviral therapy resulted in increased expression of the CD4 T-cells. To summarize the immune modulator role of MIP, it may be postulated that MIP evokes a balanced immune cum inflammatory response which helps in restoration of the tissue microenvironment and keeps check on cytokine storm. An added advantage of using MIP in developing countries like India includes drugs being easily available as cheap preparations and is not associated with any serious side effects associated with its use. 19 Accordingly, these findings led us to hypothesize the beneficial role of MIPin severely ill COVID-19 patients. Therefore, the present clinical study was conducted to gather initial experience of evaluating the role of MIP in severely ill COVID-19 patients. Patients undergoing treatment with MIP were made aware of their treatment by medical staff. 12, 14 Exclusion criteria were defined as (i) patients died within 48 h of hospitalization, (ii) patients suffering from other pulmonary morbidities, (iii) patients below 18 years of age, (iv) patients having more than two associated comorbidities, (iv) patients where written consent could not be obtained. In the comparator group, patients received standard/symptomatic therapy, which comprised of Ivermectin 12 mg twice daily for 3 days, doxycycline 200 mg stat followed by 100 mg twice daily for 4 days, and azithromycin 500 mg once daily for 5 days. Patient information was obtained from the hospital master data file and medical records of patients. Variables considered of clinical relevance in the present study included Immune, inflammatory, all-cause mortality, the need for ventilator support. In both groups above, parameters were considered at the time of initiation/administration of MIP and on the 5th-day posttreatment. CT scan was performed on an average 5.8th day after the onset of symptoms as per the method described in our earlier publication 15 and on the 5th day after randomization. Briefly, images were taken in single inspiration breath-hold, and two radiologists separately analyzed CT images. The semiquantitative method was used to calculate the percentage of lung involvement and was classified as mild (<25%), moderate (25%-50%), severe (51%-75%), and diffuse (>75%). We identified all-cause mortality during hospitalization in both groups as the primary outcome, while secondary outcomes considered in the present study included differences in mean oxygen requirement, oxygen saturation, and change in immune cum inflammatory markers. Short-term safety of MIP was evaluated on the basis of liver function test, kidney function test, hemoglobin level, death, and premature discontinuation of treatment (in MIP group). In the present interventional study, we did not conduct a prior sample size calculation. The MIP cohort (n = 105) was a sample of convenience and included all patients treated with MIP. The BST control sample size was estimated by matching at 1:2 (cases to controls) by propensity score analysis. Continuous variables were expressed as mean ± SE; interquartile range while categorical variables were expressed as count/percentage with odds ratio. Mann-Whitney U test, and categorical data were compared by χ 2 test. Time-dependent events in the MIP group were compared by a two-sided log-rank test (hazard ratio [HR] and 95% confidence interval) on Kaplan-Meier survival analysis across days of hospitalization. High-sensitive C-reactive protein (Hs-CRP) concentration across different days of treatment was compared by repeated-measures mixed-model, and p < 0.05 was considered statistically significant, and statistics were performed with IBM SPSS Statistics, version 20 and statographics 18. 22 A total of 105 patients were included in the MIP group. Similarly, from the retrospective historical control group, out of 1894 patients admitted from March 2020, 210 BST control patients were identified to serve as a comparator group for the MIP group. Henceforth clinical, biochemical, and radiological characteristics between these groups were compared (Tables 1 and 2 ). On the day of randomization when ILs and TNF-α responses of patients were compared in two treatment arms, we could not find any significant difference in pretreatment values of IL-1, IL-2, IL-6, and TNF-α. On the 5th day of treatment, a significant reduction was Associations between increased serum inflammatory factors, interleukins (IL-1; IL-2, IL-4, IL-6, IL-10, and INF-γ) and TNF-α levels with hospital stay in coronavirus disease of 2019 patients (Pearson's product-moment correlations) correlation analyses were conducted between variables and were considered significant at p < 0.05; p < 0.01; p < 0.0001. Hs-CRP, high-sensitive C-reactive protein SHAH ET AL. (Table 4) . From Table 4 On the 5th day of treatment, total leukocyte count (TLC) levels in patients. 32 patients. The study reported a significant reduction in C-reactive protein (an inflammatory marker) in those patients who were treated with MIP. 41 Furthermore, a recently genomic-wide association study has attributed the immune-modulatory role of MIP to high antigenic potential. 42 MIP, as an adjuvant to standard therapy against tuberculosis, revealed immune modulation and regulation of inflammatory process in later part treatment is perhaps useful in the restoration of normal tissue architecture. 43 Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Immunomodulation in COVID-19 Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts Remdesivir and coronavirus disease 2019 (COVID-19): essential questions and answers for pharmacists and pharmacy technicians Nucleoside analogs and nucleoside precursors as drugs in the fight against SARS-CoV-2 and other coronaviruses Molecular basis of the therapeutical potential of clove (Syzygium aromaticum L.) and clues to its anti-COVID-19 Utility Principles and challenges in anti-COVID-19 vaccine development CSIR fights COVID-19. Accessed COVID-19: consider cytokine storm syndromes and immunosuppression Role of cytokines as a doubleedged sword in sepsis Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species Efficacy and safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts Induction of lepromin positivity and immunoprophylaxis in household contacts of multibacillary leprosy patients: a pilot study with a candidate vaccine, Mycobacterium w Focusing on a unique innate memory cell population of natural killer cells in the fight against COVID-19: harnessing the ubiquity of cytomegalovirus exposure Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung In vitro characterization of T cells in Mycobacterium w-vaccinated mice Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study National Health Commission of the People's Republic of China Spectrum of chest computed 348 tomographic (CT) findings in coronavirus disease-19 (COVID-19) patients in India A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19 Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial Compassionate use of remdesivir for patients with severe COVID-19 A real-time dashboard of clinical trials for COVID-19 An overview of some potential immunotherapeutic options against COVID-19 Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality Anakinra for severe forms of COVID-19: a cohort study Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury On the use of corticosteroids for 2019-nCoV pneumonia Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyper inflammation: a retrospective cohort study Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients Mycobacterium indicus pranii supernatant induces apoptotic cell death in mouse peritoneal macrophages in vitro TLR9 and COVID-19: a multidisciplinary theory of a multifaceted therapeutic target A randomized trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1 Immunoprophylactic effects of the anti-leprosy MIP vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years Biomarkers of treatment response in clinical trials of novel antituberculosis agents Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment Repurposing of Mycobacterium indicus pranii for the severe form of COVID-19 patients in India: A cohort study The authors are obliged to all the staff members of Chest Disease Hospital Srinagar, India, for their kind support in the supervision of all COVID-19 patients. The authors declare that there are no conflict of interests. The raw data used to support the findings of the present study are accessible from the corresponding author upon request.